Quality of life (% max score of Q‐LES‐Q‐SF) ‐ Any dose Scale from: 0 to 100 (better) · treatment‐resistant depression in adults
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
2 findings from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).
1 finding from 1 review
Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60… showed no clear difference in response (≥50% reduction in MADRS score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d to 60… (low certainty).
1 finding from 1 review
Remission ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Adverse events (disease‐related: all physical symptoms); · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in dyspnoea score · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in exercise tolerance · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in hospital utilisation ‐ not measured · chronic obstructive pulmonary disease (COPD) with depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response of depression · adults with psychotic depression
It is very uncertain whether antidepressant plus antipsychotic changes clinical response of depression compared with placebo (very low certainty).
1 finding from 1 review
Leaving the study early · adults with psychotic depression
It is very uncertain whether antidepressant plus antipsychotic changes overall dropouts compared with placebo (very low certainty).
1 finding from 1 review
Depression remission · adults with psychotic depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in depression severity from baseline · adults with psychotic depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with psychotic depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ dropouts due to adverse effects · adults with psychotic depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response of depression · adults with psychotic depression
Antidepressant plus antipsychotic may leads to higher clinical response of depression compared with placebo plus antipsychotic (low certainty).
1 finding from 1 review